

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 68838

Title: Management of SARS-CoV-2 infection is a major challenge in patients with

lymphoid malignancies: Warrants a clear therapeutic strategy

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06060139
Position: Peer Reviewer
Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: India

Author's Country/Territory: Germany

Manuscript submission date: 2021-06-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-06 12:03

Reviewer performed review: 2021-06-06 12:04

Review time: 1 Hour

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer statements

Peer-Review: [Y] Anonymous [] Onymous

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript is well written and need of the present times.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 68838

Title: Management of SARS-CoV-2 infection is a major challenge in patients with

lymphoid malignancies: Warrants a clear therapeutic strategy

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05935566 Position: Peer Reviewer

Academic degree: MBBS, MS

Professional title: Assistant Professor, Doctor

Reviewer's Country/Territory: India

Author's Country/Territory: Germany

Manuscript submission date: 2021-06-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-07 04:41

Reviewer performed review: 2021-06-07 07:54

Review time: 3 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Dear author, Well written article Regards



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 68838

Title: Management of SARS-CoV-2 infection is a major challenge in patients with

lymphoid malignancies: Warrants a clear therapeutic strategy

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05401746 Position: Peer Reviewer

Academic degree: BM BCh, MA, MRCP, PhD

Professional title: Associate Professor, Consultant Physician-Scientist, Senior Lecturer

Reviewer's Country/Territory: United Kingdom

Author's Country/Territory: Germany

Manuscript submission date: 2021-06-05

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-07 15:40

Reviewer performed review: 2021-06-15 17:28

Review time: 8 Days and 1 Hour

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [Y] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[]Yes [Y]No



Baishideng Publishing

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Sahu and colleagues have authored a letter in response to a recent review in this journal. The letter makes a few good points but there are a few errors which need attention -Given the title it would be useful if the authors could make some suggestions as to what this therapeutic strategy might involve - The article by Abid et al that they reference several times is a viewpoint and does not contain original data. In addition it reviews COVID-19 treatment in the context of immune checkpoint blockade and CAR T cells and makes a few recommendations for this type of treatment - it does not mention standard chemo(immuno)therapy which the vast majority of lymphoma patients will receive -They reference this paper again after quoting figures that 85% of patients with lymphoid malignancies will be admitted with 9% needing ICU and 34.5% mortality - but these figures are not in this reference - They touch on the efficacy of COVID-19 vaccines in lymphoma patients as a result of very recent publications. As this data has been published since the Riches review this would be a good area to expand upon